Original reporting and analysis on the stories shaping biotech.
AstraZeneca is reportedly negotiating a deal worth up to $15 billion with Summit Therapeutics for ivonescimab, a bispecific antibody that beat Keytruda in a head-to-head lung cancer trial. If it closes, it would be one of the largest licensing deals in biopharma history.
Eli Lilly just made all six doses of Zepbound available in cheaper single-dose vials at $449/month, roughly $637 less than the pen's list price. With Novo Nordisk slashing Wegovy prices in response, the GLP-1 obesity drug market is now in a full-blown price war.
Anthropic, the company behind Claude, quietly built a physical biology lab in the Bay Area. It's not just selling AI to pharma anymore; it's running real experiments, and that changes the competitive calculus for everyone in AI drug discovery.
The FDA just approved a drug combo that targets breast cancers smart enough to dodge hormone therapy. Eli Lilly's imlunestrant plus abemaciclib is the first approved combination built specifically for ESR1-mutated tumors, and it nearly doubled the time patients stayed stable in trials.
Intellia's CRISPR gene-editing therapy reduced hereditary angioedema attacks by 87% with a single infusion in a pivotal phase 3 trial. With FDA Priority Review granted and a decision date set for March 2027, in vivo gene editing just got very real.
The UK is pouring £250 million into a massive new biosecurity research campus in Essex, betting it can keep pace in the global race for biotech supremacy. But with the facility not fully operational until 2038, the real question is whether ambition can survive a 12-year timeline.
A tiny California biotech just showed its cannabinoid drug could double semaglutide's weight loss in obese mice. The catch? It was originally designed to help cancer patients gain weight. The obesity arms race just got a lot weirder.
The U.S. Treasury is drafting rules that would let most pharma licensing deals with China continue, targeting only pathogen and weapons-related biotech. After $137 billion in cross-border deals last year alone, the biotech industry may have just dodged a massive policy grenade.
Curium is paying up to $8 billion to acquire Lantheus, combining two radiopharmaceutical giants in what could be the defining deal of nuclear medicine's hot streak. The merger signals that radioactive cancer therapies aren't a niche anymore; they're the next arms race in oncology.
Electra Therapeutics just raised $350 million in one of 2026's biggest biotech IPOs, betting on a protein family most people have never heard of. The upsized deal signals serious investor appetite, but the real test is still ahead.
Xenon Pharmaceuticals hit pause on its phase 3 depression trials after patients experienced psychosis, a nightmare side effect for a drug designed to treat the mind. The stock cratered 25%, analysts are split, and the race to fix depression just got a lot more complicated.
The FDA just approved the first-ever treatment for Sanfilippo syndrome, a fatal childhood brain disease. Ultragenyx's one-time gene therapy costs $3.95 million per dose, and the company desperately needed the win after its stock cratered weeks earlier.
Genentech just dropped $190 million upfront on a Hanmi Pharmaceutical obesity drug that's never been tested in a human, with the total deal potentially reaching $2.3 billion. The molecule promises something GLP-1 drugs can't: burning fat while building muscle.
Novo Nordisk just committed up to $1.4 billion to a tiny Danish biotech working on ring-shaped molecules most pharma companies gave up on. The bet: turning injectable blockbusters into pills could reshape cardiometabolic medicine, and Orbis Medicines claims to have cracked the chemistry.
England's NHS just approved a cancer drug it rejected two years ago, ending a standoff that left patients watching from the wrong side of the Scottish border. The story behind the reversal says a lot about the collision between breakthrough drugs and public healthcare budgets.
SK Biopharmaceuticals just dropped $315 million on a Parkinson's drug that hasn't even picked its final molecule yet. The dual-target approach is scientifically intriguing, but the timing, right after the field's biggest clinical failure, makes this one of 2026's boldest preclinical bets.
Novartis killed its ALS drug lifonebart after a Phase 2 trial missed every endpoint, adding to a decades-long streak of industry failures against one of neuroscience's most stubborn diseases. But the company's next move tells a different story.
Bristol Myers Squibb just killed a $100 million drug program before its trial even finished, and the fallout goes way beyond one company's balance sheet. The world's only clinical-stage degrader-antibody conjugate is now dead, leaving an entire emerging drug class without proof it works in humans.
Vera Therapeutics' Trutakna posted a 76% reduction in kidney disease progression with zero patients needing dialysis or transplant over two years. Those are the kind of numbers that make nephrologists do a double-take, and the IgA nephropathy treatment landscape may never look the same.
The FDA just approved the first new treatment for kidney disease in Type 1 diabetes patients since the early 1990s. Here's why it took three decades, what Bayer's Kerendia actually proved in trials, and what it means for a quarter-million Americans who've been waiting.
AnaptysBio's rosnilimab does the exact opposite of cancer immunotherapy, activating PD-1 instead of blocking it, and just posted "JAK-like" efficacy in a 424-patient rheumatoid arthritis trial. If the results hold up, it could open an entirely new treatment lane for autoimmune disease while sidestepping JAK inhibitors' serious safety baggage.
Novartis paid $125 million to own Sironax's brain delivery platform, a technology designed to sneak large-molecule drugs past the blood-brain barrier. It's the latest move in a quiet but relentless shopping spree that reveals exactly where Novartis thinks the future of neuroscience is heading.
Join thousands of biotech professionals who start their day with our free, daily briefing.